The hepatitis B virus (HBV) surface antigen (HBsAg) is a complex protein, and understanding accurately the impact of amino acid changes on the antigenicity of the immunodominant a determinant must take this complexity into consideration. Epitope mapping with four mAbs was used to phenotype HBsAg directly from patients' sera to investigate the effect of mutations in their native genetic backbone. The expected mAb reactivity was established initially for samples harbouring 'wild-type' HBsAg sequences across genotypes A-E. The alteration of HBsAg antigenicity, defined by mAb epitope loss, was demonstrated in a number of samples with sequence-inferred amino acid changes. Individual mutations within the mapped epitopes to which the mAbs were directed usually affected their binding. However, the loss of more than one epitope was observed as the number of mutations within a sequence increased. Conversely, not all mutations occurring in the a determinant altered the HBsAg conformation. The genotype backbone, the specific amino acid substitution and amino acid changes occurring outside the major antigenic region appeared to be important in determining expression of the predicted epitope loss. These data clearly demonstrate that sequence-based methods alone may not accurately define HBsAg phenotype. This phenotyping methodology allows for the rapid and accurate identification of antigenically altered viruses and will greatly enhance current HBV surveillance, research and diagnostic activities. The data generated can be used to inform on public health issues relating to prevalence, transmission and impact of HBsAg mutants in HBVinfected populations.
INTRODUCTION
Immunization programmes and potent oral antiviral drugs have assisted in the global control and treatment of hepatitis B virus (HBV) infections. However, the pressure asserted by both of these interventions leads to the evolution and selection of mutations in the two genes that code for the hepatitis B surface antigen (HBsAg) and the viral polymerase (Carman, 1997; Hsu et al., 1999; Zoulim & Locarnini, 2009) . As a result of the overlapping organization of the HBV genome, codon changes selected for in one gene can lead to coding changes in the other gene (Clements et al., 2010) . Either or both changes may lead to altered functionality of their respective proteins. A good example of this is where the polymerase mutations pV173L and pM204V associated with established resistance to the drug lamivudine appear to alter the antigenicity and epitope profile of HBsAg (Sloan et al., 2008; Torresi et al., 2002) .
It seems likely that both vaccine and antiviral treatment will select, on a population basis, viruses bearing mutations that alter the normal conformation of HBsAg. This raises concern over any potential hazards to global immunization posed by HBsAg mutants, especially as we currently live globally in an era of increased use of immunization, oral antivirals and increased population movement. It remains difficult to comment on the impact of these mutant viruses on current public health control policies both globally and specifically in the UK, as there are no population-based surveys providing comprehensive surveillance data on the existence of such viral infections, let alone any formal measure of their prevalence. In particular, in the UK we do not know how common such HBsAg variants are in our HBV-infected populations, whether these viruses are escaping our control policies or even whether they are being transmitted to individuals who have been immunized previously against HBV.
One reason for the paucity of information is that the identification of HBsAg mutant-bearing viruses has relied principally on direct sequencing of HBV DNA from patients' sera. An assumption implicit in such studies is that the DNA sequence predicts antigenicity. However, HBsAg is a complex three-dimensional structure comprising intra-membranous and extra-membranous leaflets (Chen et al., 1996; Prange & Streeck, 1995) . It is known that the effect of mutations on the HBsAg conformation is variable and that the genetic backbone of the virus influences considerably how singlecodon changes impact on the epitope display of HBsAg (Beale et al., 2010) . As a result, it is not possible to infer accurately changes in antigenicity from direct consensus sequencing. In order to understand better the part played by codon changes in the alteration of HBsAg expression in vivo, we have used epitope mapping ex vivo to define changes in antigenicity of plasma HBsAg from patient samples and compared the observed epitope profile with the predicted amino acid sequence of the HBsAg protein. The Luminex platform (BioRad) provides a method of interrogating protein-antibody interactions on discrete and separately identifiable bead solid phases read by laser collimetry. In this instance, we used the technology to measure the interaction of plasma HBsAg with four mAbs directed at different epitopes of the a determinant of HBsAg. Our data indicated that the mechanism of epitope loss may be complex, and that investigating HBsAg mutations in the context of their natural backbone is essential to predict the impact of amino acid variation on the conformation of this structure.
RESULTS

Assay dynamics
Serial half log 10 dilutions in the assay diluent of genotype A serum containing a high level of wild-type HBsAg repeatedly demonstrated that, under the described conditions, the assay was able to reliably detect 2.5 IU HBsAg ml 21 with a test/ negative fluorescent signal of~50. Increasing HBsAg input gave a linear increase in fluorescence for all four solid phases up to a level of 1000 IU ml
21
, at which point the proportionate increase in fluorescence decreased as the solid phase approached saturation (Fig. 1) . For practical purposes, a sample input giving a fluorescent intensity of ¢100 and ¡20 000 was considered necessary for mapping to be valid. In order to avoid having to titrate formally the samples to be mapped, a series of blind dilutions of 1 : 100, 1 : 300 and 1 : 1000 in the assay diluent usually provided this level of reactivity, corresponding to an HBsAg level of around 100 IU ml
.
Normal epitope profiles of genotypes A-E
As one of the uses of this method would be to apply the Luminex approach for investigating sera in the absence of prior knowledge of the virus genotype, we determined the epitope profiles of a panel of 152 sera of known genotype and phylogenetically defined wild-type sequence in order to define the range of epitope reactivity. Each serum was assayed across dilutions of 1 : 100, 1 : 300 and 1 : 1000 to examine the relative performance of each of the mAbs for capturing HBsAg. Analysing the reactivity of each solid phase for a given sample and ascribing the reactivity as a proportion of the total signal enabled a statistical description of the expected performance of the four solid phases for capturing HBsAg of each of the five genotypes A-E examined (Fig. 2) . These data and the expected distribution limits shown were used as comparators irrespective of genotype for the subsequent analysis of sera containing HBsAg expected to show variant antigenicity. Broadly, the mAb proficiencies for HBsAg binding were similar, although an increased range of fluorescent reactivities was noted for mAb H3F5 capturing genotype E virus antigens (Fig. 2) . One sample repeatedly showed epitope deletion for mAb P2D3, and the loss of this reactivity resulted in the remaining mAbs contributing a higher proportion of the total fluorescent signal and consequently perturbed their ratios (Fig. 2) epitopes. This sample was genotype E and carried no identifiable codon changes to account for epitope loss. Two samples repeatedly showed enhanced D2H5 reactivity (genotypes A and D) for no discernible reason. A similar anomalous result was noted for HB04 and a genotype E sample.
Investigation of the epitope profile of four anomalous sera
Using the comparator data to define the expected epitope proportions for known genotypes, it was possible to interrogate the four samples that had caused diagnostic problems and show that their profiles were altered. Significant epitope deletion was noted, with the reactivity for second-loop epitopes (mAb D2H5) being particularly attenuated in three of the samples (Table 1) . Sample D carried coding changes in the mini loop and first loop that impacted on P2D3 reactivity.
Investigation of 38 sera inferred by sequencing to contain HBsAg variants
Epitope profiles of 38 samples with inferred coding changes were investigated using 2 SD of the median values determined from the statistical analysis of the 152 wildtype data to define the normal limits. Twenty samples were considered to have significant second-loop codon changes. Seventeen of these exhibited significant loss of mAb D2H5 reactivity, ranging from partial to nearly complete loss of reactivity (Table 2 ). In four of these samples, the loss included an effect on mAb HB04 binding, and in a further one sample an effect was seen on mAb H3F5 binding. The remaining three samples of the 20 did not show detectable epitope alteration.
Eight samples were considered to have mini-/first-loop codon changes. Five showed reduced reactivity to mAb P2D3, with one of these additionally involving reduced mAb H3F5 reactivity. The remaining three showed no epitope change.
Seven samples were considered to have codon changes involving both the mini/first and second loops. All seven showed a changed epitope profile, with some exhibiting virtually complete elimination of epitopes for mAbs D2H5, H3F5 and HB04 and for mAb P2D3. Of the three samples considered to have changes outside codons 120-150, one showed reduced mAb P2D3 reactivity and another showed loss of mAb H3F5 reactivity.
DISCUSSION
The external envelope of HBV exists in serum as three morphological entities of which the 22 nm particle is dominant (Le Bouvier et al., 1972) . The a determinant is the most important and the one to which natural, vaccineinduced and diagnostic antibodies are directed. In order to understand better the stability of the a determinant expressed in its natural genetic backbone, we used four mAbs reactive with the a determinant of all serotypes and recognizing discrete HBsAg a determinant epitopes to map plasma HBsAg directly.
A total of 152 samples with a wild-type HBsAg sequence were recognized equally by the four mAbs and their epitope distribution provided the standards against which epitope loss could be measured. One sample failed to be captured on the P2D3 linear epitope mAb in spite of a normal inferred sequence of the epitope and warrants further investigation. The creation of normal limits for the epitope profile across genotypes A-E will permit the blind use of the assay for surveillance purposes. The four diagnostic samples that had repeatedly given inconsistent results in commercial HBsAg detection assays and had at the time of their identification caused issues in patient diagnosis and management (Rice, 1988) clearly showed an altered HBsAg phenotype with defined epitope loss. This observation confirmed that the amino acid changes seen within the HBsAg gene were eliminating the conformation of the protein and, more importantly, that the epitope mapping assay was able to identify clinically significantly altered HBsAg phenotypes. Loss of both conformational epitopes (samples A-C) and a linear epitope (sample D) was demonstrated.
Comparing the phenotypic epitope loss with the predicted deletion from sequencing provided a unique opportunity to determine the accuracy of genotypic prediction of HBsAg antigenicity. Interestingly, epitope alteration was demonstrated in some but not all samples in the panel of 38 selected to have significant codon changes in HBsAg and ranged from complete epitope loss (samples 2, 14, 29 and 35) to a minimal reduction (samples 9, 10, 15 and 33) ( Table 2) . In some instances, a single amino acid change within the major antigenic region, such as the classical immune escape variant G145R (sample 2), was sufficient to result in major alteration of the HBsAg conformation. In the main, individual mutations occurring in the putative mini/first loop or second loop affected binding of the mAbs whose epitopes mapped to these regions. However, the loss of more than one epitope was observed as the number of mutations within a sample increased or became more complex. Multiple second-loop mutations or mini-/ first-and second-loop combination mutations (samples 13 and 29) resulted in the loss of both the D2H5 and H3F5 epitopes. Nevertheless, specific combinations of mutations were not predictive of which epitope would be lost, again demonstrating the complexity of the HBsAg conformation and the inherent difficulty of inferring a phenotype accurately. Sample 30 provided a good example of this difficulty, harbouring both mini-and first-loop mutations that impacted on D2H5 and H3F5 reactivity but not on the P2D3 epitope, which would have been predicted.
Not all mutations occurring within the major antigenic region predicted to cause epitope deletion led to the alteration of HBsAg antigenicity. Samples 18-20, 27 and 28, although harbouring mutations in the second loop and mini loop, nevertheless expressed a normal epitope profile. This suggests that some amino acid changes or combinations of amino acid changes can be tolerated within the HBsAg structure because the protein backbone in which they occur does not permit the expression of the predicted codon-change phenotype. One speculates this could be a primary feature of the backbone or may have been acquired by additional but unidentified compensatory changes that revert the phenotype to 'normal'. Sample 29 carrying firstand mini-loop mutations similar to sample D would be predicted to show deletion of the P2D3 epitope motif but retained this epitope expression. Resolution of this phenomenon can only be addressed by back mutation and expression in mammalian cells, and such studies are planned.
The effect of amino acid changes at a given codon often depends on the substituting amino acid. Whilst the D144A change always resulted in epitope loss, the D144E change had no impact. Similarly, G145A caused much less perturbation than G145R. In addition, the genotype of the backbone influenced the impact of the amino acid substitutions. The same codon P120S change existed in samples 24 (genotype B) and 27 (genotype D) producing a mutant and wild-type phenotype, respectively. Similar disparities in epitope loss were noted with the I110L change in samples 37 (genotype E) and 38 (genotype D), in this case producing a mutant and wild-type phenotype, respectively.
Codon changes occurring outside the putative major antigenic region further complicated matters as they too led to significant alteration of HBsAg antigenicity. A 4 aa insertion at codon 119 in (sample 36) and a I110L mutation (sample 37) led to a reduction in H3F5 and P2D3 reactivity, respectively. Distant amino acid changes occurring towards the C-terminal end of the protein had some influence on the major antigenic region. Samples 20 and 27 unexpectedly displayed a wild-type phenotype yet harboured a G145R and P120S mutation, respectively. Samples 20 and 27 both bore additional mutations at the C-terminal end (I195T and V224A). A similar 'epitope rescue' phenomenon has been described previously with site-directed mutagenesis-derived recombinant HBsAg proteins (Sloan et al., 2008) . These observations are not surprising given that codon 160 is the allele responsible for the w/r serotype, a change of sufficient magnitude to be detectable in an Ouchterlony counterimmunodiffusion gel.
This study deliberately set out to use only native HBsAg in contrast to the use of site-directed mutagenesis-generated recombinant HBsAg where codon change may be imposed on a genetic backbone (Coleman et al., 1999; ServantDelmas et al., 2012) . If we make the assumption that the circulating HBV DNA represents the template from which HBsAg is translated, one may wish to infer the phenotype of the resulting HBsAg. The data presented here highlight why sequence information on its own may not be accurate and underline the need for phenotype-based methods when assessing the impact of observed amino acid changes. They also reinforce the view that phenotypic investigations into HBsAg mutants must be undertaken in the context of the whole genetic backbone of that protein. Studying a single-codon HBsAg mutation in isolation or in a laboratory-based and artificially substituted backbone may not give an accurate understanding of its impact in vivo on HBsAg antigenicity. We believe that it would be better to use natural backbones for reverse genetics, and the backbones described here will provide a suitable base on which to take forward these studies.
METHODS
Patient samples. Serum or plasma samples referred to the Microbiology Services Colindale for HBV sequence analysis were used in this study. Genotype and sequence data across the entire HBsAg ORF were generated as described previously . Genotype-specific alignments of inferred coding sequences were prepared by collation of 152 samples covering genotypes A-E (A, n531; B, n530; C, n529; D, n531; E, n531) whose inferred amino acid sequence from HBV DNA consensus sequencing was considered to be representative of a genotype-specific wild-type virus. A set of four samples known to have an anomalous reactivity in diverse immunoassays for HBsAg with known HBsAg codon changes was used to demonstrate the principle of the assay. In all cases, one or more primary diagnostic screening tests had failed to detect HBsAg. Briefly, the donors of samples A and B were haemodialysis patients with failed renal transplants, the former being chronically infected and HBV e antigen (HBeAg) seropositive and described previously (Rice, 1988) , and the latter undergoing an acute reactivation. Donors of samples C and D were chronically infected healthy HBeAgseropositive antenatal mothers. None was known to have detectable anti-HBV surface antigen (HBsAg) or known to have been immunized. A further panel of 38 samples referred to our laboratory for sequence analysis and whose HBsAg sequences carried amino acid substitutions divergent from the consensus genotype-specific alignments predicted to alter antigenicity were analysed. Normal human plasma was prepared as a pool of plasma samples negative for all markers of HBV supplied by NHS Blood and Transplant.
Antibodies. Supernatant fluids from four hybridomas secreting mAbs raised against native HBsAg were used for the epitope mapping. The parent hybridomas had been selected during initial screening for anti-HBs on the basis of strong and equivalent reactivity with all members of the 1975 Paris genotype panel (Couroucé et al., 1976) . mAb P2D3 recognizes a first-loop linear epitope between codons 121 and 129 (Ijaz et al., 2003) ; mAbs H3F5, D2H5 and HB04 were raised against a mixture of ad/ay HBsAg (Tedder et al., 1983) and recognize conformational epitopes. Tentative mapping data indicated that H3F5 bound to epitopes between codons 131 and 142, whilst D2H5 and HB04 recognized similar epitopes in the second loop between codons 142 and 147 (J. Duncan, personal communication). Affinitypurified polyclonal anti-HBs was kindly provided by Abbott Murex (now DiaSorin) and conjugated with R-phycoerythrin (RPE; AbD Serotec).
Microsphere beads. Purified rabbit anti-mouse IgG (10 mg; AbD Serotec) was covalently coupled separately in accordance with the manufacturer's instructions to each of four sets of 1 million microsphere beads (Bio-Rad Laboratories), each set corresponding to an individually distinct population identifiable by internal dye labels. Following blocking with PBS containing 1 % BSA (PBS/BSA), each set of anti-mouse IgG-coupled beads was incubated overnight with 500 ml of one hybridoma supernatant fluid such that one mAb of a given specificity was coupled indirectly to one of the uniquely identifiable microsphere sets. The microspheres were then washed twice in PBS/BSA and stored in the dark at 4 uC until required for use. For epitope mapping, a mixed microsphere reagent was prepared from equal quantities of each of the four microsphere sets indirectly coated with the different mAbs.
Assay protocol. Serum or plasma containing HBsAg was diluted 1 : 100, 1 : 300 and 1 : 1000 in 0.8 M guanidinium chloride. This chaotrope was used to reduce low-avidity interactions and improve the discriminatory power of the assay. One hundred microlitres of each dilution was added to filter-bottom plates pre-wetted with PBS. After gentle vortexing prior to use, 25 ml of the mixed microsphere reagent was added to each well. Following incubation on a shaker at 37 uC for 2 h, the plate was washed three times with PBS containing 0.05 % Tween (PBS/Tween). RPE-labelled polyclonal anti-HBs diluted 1 : 5000 in PBS/BSA was then added and the plate incubated with shaking for 1 h at room temperature. Finally, the wells were washed twice with PBS/Tween before analysis on a Bio-Plex 200 platform (Bio-Rad Laboratories).
The fluorescent intensity of the RPE-labelled polyclonal anti-HBs bound to the captured HBsAg on each mAb was measured for 100 microspheres of each mAb specificity.
Analysis of epitope density. The ratio of the fluorescence signal for each mAb to the geometric mean fluorescence within a sample for all four mAbs was calculated for the population of 152 samples covering genotypes A-E. The expected range of these ratios was used to identify the eliminated epitopes and was calculated using the median ratio and then setting limits as: lower510[log(median)22 SD] and upper510[log(median)+2 SD], where median is the median ratio and SD is a robust estimate of the SD of the logged ratios. The robust method used to calculate the SD was 1.48266median absolute deviation from the median (Rousseeuw & Croux, 1993) .
For ease of viewing the data, the fluorescence of each mAb was expressed as the percentage of the total fluorescence sum of all four mAbs observed for that sample. Where epitope loss was identified using the algorithm described above, its fluorescence value is highlighted in bold in Tables 1 and 2 .
Assay testing. To determine the level of HBsAg over which specific reactivity could be determined, a serum sample from a known chronically infected individual (genotype A, predicted wild-type phenotype) containing high levels of HBsAg was used to prepare serial half log 10 dilutions in guanidine buffer containing between 1 and 250 000 IU ml 21 . These were subjected to the assay.
To determine the reactivity profiles and variability generated by the inferred naturally occurring amino acid sequence variance across the HBV genotypes A-E, each of the 152 samples containing phylogenetically defined wild-type HBsAg was subjected to the assay.
To determine the reactivity profiles of viruses carrying variant HBsAg, the first four samples (A-D) each individually known to have caused anomalous results on HBsAg testing were subjected to testing.
To determine further the range of codon changes associated with epitope elimination, the 38 samples (1-38) carrying inferred amino acid substitutions characterized by consensus sequencing of the HBV s gene were also subjected to the assay. The amino acid changes predicted to affect antigenicity were variously within the putative mini loop, the first loop or the second loop, or just upstream of the a determinant.
